Merck Patentgesellschaft
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 9 name spellings.
12
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 5, 2027The maintenance fee for Ce(IV)-initiated graft polymerisation on polymers containing no hydroxyl groups (US 9,303,098) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,858,376 | Ninhydrin and ionic liquid reagent mixture and method for the visualization of amino acids and peptides In force · From the USPTO record | In force | From the USPTO record | |
| US 7,803,434 | Liquid-crystalline medium In force · From the USPTO record | In force | From the USPTO record | |
| US 7,731,865 | Liquid-crystal medium In force · From the USPTO record | In force | From the USPTO record | |
| US 7,854,970 | Liquid-crystalline medium In force · From the USPTO record | In force | From the USPTO record | |
| US 8,415,352 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes In force · From the USPTO record | In force | From the USPTO record | |
| US 7,838,090 | Liquid-crystalline medium and liquid-crystal display In force · From the USPTO record | In force | From the USPTO record | |
| US 8,383,838 | 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,815,859 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,637,522 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes In force · From the USPTO record | In force | From the USPTO record | |
| US 8,329,692 | Pyrimidinyl pyridazinone derivatives In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 14: 3 patents in force now held by others · 174 lapsed for an unpaid fee · 82 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 abandoned · 22 no status recorded